| Clinical Scenario Management . | Inactive IBD With Suspected COVID-19 . | Active IBD With Suspected COVID-19 . | Inactive IBD With Confirmed Mild COVID-19 . | Active IBD With Confirmed Mild COVID-19 . | Inactive IBD in COVID-19, Hospitalized . | Active IBD With Severe COVID-19, Hospitalized . |
|---|---|---|---|---|---|---|
| Continue immunosuppressants and biologics Plus fast tapering of corticosteroids | 44.2%a | 65.3% 25.5% | 26.5% | 40% 12% | 6% | 18% 8% |
| Withdraw immunosuppressants and biologics Plus fast tapering of corticosteroids | 46.2% | 14.3% 2% | 58.5% | 38% 8% | 84% | 58% 26% |
| Withdraw immunosuppressants/continue biologics | 5.8% | 4% | 9.4% | 20% | 6% | 18% |
| Withdraw biologics/continue immunosuppressants | 3.8% | 16.3% | 5.6% | 2% | 4% | 6% |
| Clinical Scenario Management . | Inactive IBD With Suspected COVID-19 . | Active IBD With Suspected COVID-19 . | Inactive IBD With Confirmed Mild COVID-19 . | Active IBD With Confirmed Mild COVID-19 . | Inactive IBD in COVID-19, Hospitalized . | Active IBD With Severe COVID-19, Hospitalized . |
|---|---|---|---|---|---|---|
| Continue immunosuppressants and biologics Plus fast tapering of corticosteroids | 44.2%a | 65.3% 25.5% | 26.5% | 40% 12% | 6% | 18% 8% |
| Withdraw immunosuppressants and biologics Plus fast tapering of corticosteroids | 46.2% | 14.3% 2% | 58.5% | 38% 8% | 84% | 58% 26% |
| Withdraw immunosuppressants/continue biologics | 5.8% | 4% | 9.4% | 20% | 6% | 18% |
| Withdraw biologics/continue immunosuppressants | 3.8% | 16.3% | 5.6% | 2% | 4% | 6% |
aPercentages represent the number of respondents.
| Clinical Scenario Management . | Inactive IBD With Suspected COVID-19 . | Active IBD With Suspected COVID-19 . | Inactive IBD With Confirmed Mild COVID-19 . | Active IBD With Confirmed Mild COVID-19 . | Inactive IBD in COVID-19, Hospitalized . | Active IBD With Severe COVID-19, Hospitalized . |
|---|---|---|---|---|---|---|
| Continue immunosuppressants and biologics Plus fast tapering of corticosteroids | 44.2%a | 65.3% 25.5% | 26.5% | 40% 12% | 6% | 18% 8% |
| Withdraw immunosuppressants and biologics Plus fast tapering of corticosteroids | 46.2% | 14.3% 2% | 58.5% | 38% 8% | 84% | 58% 26% |
| Withdraw immunosuppressants/continue biologics | 5.8% | 4% | 9.4% | 20% | 6% | 18% |
| Withdraw biologics/continue immunosuppressants | 3.8% | 16.3% | 5.6% | 2% | 4% | 6% |
| Clinical Scenario Management . | Inactive IBD With Suspected COVID-19 . | Active IBD With Suspected COVID-19 . | Inactive IBD With Confirmed Mild COVID-19 . | Active IBD With Confirmed Mild COVID-19 . | Inactive IBD in COVID-19, Hospitalized . | Active IBD With Severe COVID-19, Hospitalized . |
|---|---|---|---|---|---|---|
| Continue immunosuppressants and biologics Plus fast tapering of corticosteroids | 44.2%a | 65.3% 25.5% | 26.5% | 40% 12% | 6% | 18% 8% |
| Withdraw immunosuppressants and biologics Plus fast tapering of corticosteroids | 46.2% | 14.3% 2% | 58.5% | 38% 8% | 84% | 58% 26% |
| Withdraw immunosuppressants/continue biologics | 5.8% | 4% | 9.4% | 20% | 6% | 18% |
| Withdraw biologics/continue immunosuppressants | 3.8% | 16.3% | 5.6% | 2% | 4% | 6% |
aPercentages represent the number of respondents.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
